
Forkhead Bio: A biotech firm innovating cell conversion therapies for insulin-dependent diabetes.
Forkhead BioTherapeutics, founded with a mission to harness the intrinsic capabilities of cell conversion and regeneration, aims to develop transformative therapies that significantly improve patients' lives. The company focuses on innovative biotechnological solutions, with its first target indication being insulin-dependent diabetes. By leveraging advanced cell therapy techniques, Forkhead BioTherapeutics seeks to offer groundbreaking treatments that address critical unmet medical needs in the diabetes market.
Notable affiliated individuals and investors include leading experts in biotechnology and regenerative medicine, although specific names are not publicly disclosed. Key achievements of Forkhead BioTherapeutics include significant advancements in cell conversion technology and promising preclinical results that have garnered attention within the biotech community. The overall impact of the company lies in its potential to revolutionize diabetes treatment, offering hope for millions of patients reliant on insulin therapy.

SymbioCellTech
symbiocelltech.com

Stemson Therapeutics
stemsontx.com

Spheringenics

Cell BioEngines
cellbioengines.com

ViaCyte

Legend Biotech
legendbiotech.com

Forge Biologics
forgebiologics.com

Cellevolve Bio
cellevolve.com

Throne Biotechnologies
thronebio.com

Appia Bio
appiabio.com

MelliCell
mellicell.com

Fuse Biotherapeutics
fusebiotx.com

HebeCell
hebecellcorp.com

Apic Bio

Encellin
encellin.com
Companies similar to Forkhead BioTherapeutics include SymbioCellTech, Stemson Therapeutics, Spheringenics and Cell BioEngines.
Forkhead BioTherapeutics was founded in 2017.
Forkhead BioTherapeutics' headquarters is located in New York City, NY, US.
As of Mar 20, 2019, Forkhead BioTherapeutics has raised a total of $1M (USD).
Forkhead BioTherapeutics has 2 employees as of Feb 4, 2024.